Meeting
2024 ASCO Gastrointestinal Cancers Symposium
Lenvatinib plus pembrolizumab versus lenvatinib alone as first-line therapy for advanced hepatocellular carcinoma: Longer-term efficacy and safety results from the phase 3 LEAP-002 study.
Presenter
Richard S. Finn, MD
University of California, Los Angeles
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Poster Session
Session Title
Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03713593
Citation
J Clin Oncol 42, 2024 (suppl 3; abstr 482)
DOI
10.1200/JCO.2024.42.3_suppl.482
Abstract #
482
Poster Bd #
C7
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of lenvatinib (LEN) plus pembrolizumab (PEMBRO) versus sunitinib (SUN) in the East Asian subset of patients with advanced renal cell carcinoma (aRCC) from the phase 3 CLEAR trial.
Speaker: Sun Young Rha, MD, PhD
Videos & Slides
2022 ASCO Genitourinary Cancers Symposium
Efficacy and safety of nivolumab plus ipilimumab (N+I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
Speaker: Nizar M. Tannir, FACP, MD
Videos & Slides
2022 ASCO Gastrointestinal Cancers Symposium
First-line pembrolizumab plus chemotherapy versus chemotherapy in advanced esophageal cancer: Longer-term efficacy, safety, and quality-of-life results from the phase 3 KEYNOTE-590 study.
Speaker: Jean-Philippe Metges, MD, MSc
Videos & Slides
2021 ASCO Annual Meeting
Differences in the Pattern of and Response to Treatment: Not Just Race
Speaker: Elisabeth I. Heath, MD, FACP